Abstract | INTRODUCTION:
Oral contraceptive pills (OCPs) are the most frequently used form of effective, reversible contraception among women of childbearing potential. In the average risk population, OCPs may offer a protective benefit against ovarian, endometrial and colorectal malignancies. In women at high risk for breast, ovarian, endometrial or colorectal malignancies, the risk-benefit profile is less well studied. AREAS COVERED: EXPERT OPINION: For women at high risk for ovarian, endometrial and/or colorectal malignancies due to genetic susceptibilities or a strong family history, the possibility of chemoprevention with OCPs may be an attractive option; however, the potential increase in breast cancer, although small, must be considered in clinical decision-making. The ultimate decision to use OCPs in a high-risk woman should be based on a consideration of her specific genetic risk, her age, her reproductive plans and her willingness to consider surgical prophylaxis options.
|
Authors | Brittany Anne Davidson, Patricia G Moorman |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 13
Issue 10
Pg. 1375-82
(Oct 2014)
ISSN: 1744-764X [Electronic] England |
PMID | 25146351
(Publication Type: Journal Article, Review)
|
Chemical References |
- Contraceptives, Oral, Combined
|
Topics |
- Age Factors
- Breast Neoplasms
(epidemiology, etiology, genetics)
- Colorectal Neoplasms, Hereditary Nonpolyposis
(genetics, prevention & control)
- Contraceptives, Oral, Combined
(administration & dosage, adverse effects)
- Female
- Genetic Predisposition to Disease
- Genital Neoplasms, Female
(genetics, prevention & control)
- Humans
- Risk Assessment
- Risk Factors
|